Summit Creek Advisors LLC Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Summit Creek Advisors LLC increased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 37.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 228,501 shares of the medical instruments supplier's stock after purchasing an additional 62,737 shares during the quarter. Summit Creek Advisors LLC owned approximately 1.03% of LeMaitre Vascular worth $12,970,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Raymond James & Associates lifted its stake in LeMaitre Vascular by 4.1% in the third quarter. Raymond James & Associates now owns 24,827 shares of the medical instruments supplier's stock worth $1,353,000 after acquiring an additional 967 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in LeMaitre Vascular by 94.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 18,320 shares of the medical instruments supplier's stock worth $998,000 after buying an additional 8,920 shares during the period. Congress Wealth Management LLC DE boosted its position in LeMaitre Vascular by 5.1% during the 3rd quarter. Congress Wealth Management LLC DE now owns 78,534 shares of the medical instruments supplier's stock valued at $4,279,000 after acquiring an additional 3,812 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $315,000. Finally, Teacher Retirement System of Texas lifted its stake in shares of LeMaitre Vascular by 125.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 18,644 shares of the medical instruments supplier's stock valued at $1,016,000 after purchasing an additional 10,373 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 36,600 shares of the company's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the completion of the sale, the chief executive officer now owns 2,187,526 shares in the company, valued at $148,817,393.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director John A. Roush sold 7,500 shares of the firm's stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now directly owns 2,278 shares of the company's stock, valued at approximately $157,182. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 36,600 shares of the business's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $68.03, for a total value of $2,489,898.00. Following the sale, the chief executive officer now directly owns 2,187,526 shares of the company's stock, valued at approximately $148,817,393.78. The disclosure for this sale can be found here. Insiders have sold a total of 195,967 shares of company stock worth $14,072,324 over the last quarter. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded up $0.08 during mid-day trading on Monday, reaching $76.21. The stock had a trading volume of 154,350 shares, compared to its average volume of 122,732. The stock has a market cap of $1.71 billion, a PE ratio of 50.47, a price-to-earnings-growth ratio of 2.32 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $76.59. The company has a fifty day moving average price of $67.00 and a 200 day moving average price of $60.03.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm had revenue of $53.48 million during the quarter, compared to analysts' expectations of $51.50 million. During the same quarter in the previous year, the business earned $0.27 earnings per share. The company's revenue was up 13.6% on a year-over-year basis. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.78 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.84%. LeMaitre Vascular's payout ratio is 42.38%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. JMP Securities increased their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a "market outperform" rating in a report on Friday, May 3rd. Stifel Nicolaus raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Barrington Research raised their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an "outperform" rating in a research note on Friday, May 3rd. StockNews.com cut LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, KeyCorp began coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a "sector weight" rating on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $73.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.